Maraviroc Immune Recovery Study.
- Conditions
- HIV
- Registration Number
- NL-OMON24984
- Lead Sponsor
- MC Utrecht
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 130
Inclusion Criteria
1. Age 18 years or older;
2. HAART with a maximal treatment interruption of two weeks;
Exclusion Criteria
1. HAART consisting of a combination of tenofovir and didanosine;
2. Active infection for which antimicrobial treatment;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 30% increase in CD4 cell count compared with placebo.
- Secondary Outcome Measures
Name Time Method Changes in plasma HIV RNA.